Nograd Varmegyei Szent Lazar Korhaz — Clinical Trial Site

18 Registered trials

11 Currently recruiting

Organisation

Nograd Varmegyei Szent Lazar Korhaz

Location

Salgotarjan, Hungary

Identifier

ORG-100041940

Address

Fuleki Ut 54-56, 3100, Hungary

Departments

#036005: Onkológiai Centrum - Onkológia és Sugárterápiás osztály
N/A
Neurológia-Stroke Osztály
Oncology
Onkológia és Sugárterápiás Osztály
Onkológiai Centrum
Onkológiai Centrum - Klinikai Onkológiai Részleg
Onkológiai és Sugárterápiás Centrum

Clinical trials at this site (18)

Search interface

A Randomized, Placebo-controlled, Parallel Phase 2a Dose-ranging Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-0… Pending

2025-523058-16-00 Skin Toxicities Associated with Epidermal Growth Factor 4
A phase 3 study to look at the effects of 2 treatments used together (ficlatuzumab and cetuximab) on the overall survival of adults with a c… Recruiting

2023-505606-42-00 Head and Neck Squamous Cell Carcinoma (HNSCC) 5 2024-10-15
A clinical study of opevesostat and standard hormone therapy in people with prostate cancer (MK-5684-004) Recruiting

2023-504957-11-00 Metastatic castration resistant prostate cancer 5 2026-03-24
A Study of Amivantamab in Addition to Standard of Care Agents Compared with Standard of Care in Participants With Recurrent/Metastatic Head … Recruiting

2025-521917-24-00 Treatment-Naïve Recurrent/Metastatic Head and Neck Squa 5 2026-01-21
A clinical study of MK-1084 and other treatments for lung cancer (MK-1084-007) Recruiting

2024-514500-14-00 Participants with KRAS G12C-Mutant, Advanced or Metasta 5 2025-12-15
A clinical study of V940 and pembrolizumab to treat lung cancer (V940-009) Recruiting

2023-506327-29-00 Non-Small Cell Lung Cancer 5 2025-05-14
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C… Recruiting

2024-515445-42-00 Node-positive, Estrogen Receptor-positive, HER2-negativ 5 2025-03-24
C2321003: A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men with Metastatic Castration-Resistant… Recruiting

2024-511652-40-00 METASTATIC CASTRATION RESISTANT PROSTATE CANCER 5 2025-02-05
A Phase 3 study of Dostarlimab as Sequential Therapy after Chemoradiation compared to placebo in adult participants with Locally Advanced Un… Recruiting

2023-508613-17-00 Neoplasms, Head and Neck 5 2024-05-29
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamo… Recruiting

2023-506308-24-00 Recurrent or metastatic head and neck squamous cell car 10 2024-05-22
A clinical trial comparing a new treatment (MK-5684) to approved medication for advanced prostate cancer after prior hormonal therapy and ch… Recruiting

2023-504899-25-00 Metastatic castration resistant prostate cancer 5 2024-04-04
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Patients With Stage III Unresectabl… Recruiting

2023-506891-28-00 The target population of interest in this study is part 5 2022-05-02
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women with Breast Cancer Who Are Having Hormone Therapy Ended

2024-510719-31-00 Moderate to Severe Vasomotor Symptoms (VMS) 5 2025-01-24
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab Injections Before and After Surgery for the Treatment of Adult Patients wit… Ended

2023-505928-59-00 Triple Negative or Hormone Receptor low/HER2-negative B 5 2024-04-15
A Phase 3 Study of DB-1303 vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer Ended

2023-507333-17-00 HER2-low, Hormone Receptor Positive, Metastatic Breast 5 2024-04-15
A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Ended

2022-501176-26-00 Acute Ischemic Stroke and High-Risk Transient Ischemic 5 2023-08-04
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) Ended

2023-503659-88-00 Obesity 5 2023-09-05
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advan… Ended

2023-506487-13-00 Hormone receptor-positive, her2-negative advanced/metas 5